Gayle Rebovich, MD
Neurology · Providence, RINPI 1780891440
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.6% of the total across 157 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 19.5% — the pattern of someone who eats at a lot of different presentations.
Across 157 payments — averaging $20.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$629
- Teva Pharmaceuticals USA, Inc.$549
- Pfizer$320
- Amneal Pharmaceuticals LLC$300
- Novartis$299
- Lilly USA, LLC$291
- plus $830 from 17 others
What the payments were for
- Speaking & faculty fees$311%
- Food & beverage$3,07696%
- Education$1113%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 30 | $629 |
| Teva Pharmaceuticals USA, Inc. | 26 | $549 |
| Pfizer | 13 | $320 |
| Amneal Pharmaceuticals LLC | 12 | $300 |
| Novartis | 19 | $299 |
| Lilly USA, LLC | 15 | $291 |
| Genentech USA, Inc. | 8 | $169 |
| Biohaven Pharmaceutical Holding Company Ltd. | 6 | $108 |
| EMD Serono, Inc. | 5 | $92 |
| EDW Pharma, Inc. | 2 | $81 |
| Biohaven Pharmaceuticals, Inc. | 3 | $58 |
| Biogen | 3 | $57 |
| MDD US Operations, LLC | 2 | $48 |
| Eisai Inc. | 2 | $42 |
| Livanova USA, Inc. | 2 | $32 |
| Acorda Therapeutics, Inc | 2 | $31 |
| Kyowa Kirin, Inc. | 1 | $22 |
| Upsher-smith Laboratories LLC | 1 | $17 |
| Tanabe Pharma America, Inc. | 1 | $16 |
| Neurelis, Inc. | 1 | $15 |
| Argenx US, Inc. | 1 | $14 |
| Supernus Pharmaceuticals, Inc. | 1 | $14 |
| AstraZeneca | 1 | $13 |
How this compares
$3,219 in reported general payments places this provider in the 65th percentile of 86 neurology providers in Rhode Island.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BotoxOnabotulinumtoxina | 63 | $75,125 |
| Aimovig AutoinjectorErenumab-Aooe | 38 | $28,441 |
| UbrelvyUbrogepant | 14 | $14,132 |
| Nurtec OdtRimegepant Sulfate | 13 | $13,289 |
| Pregabalin | 149 | $3,740 |
| Carbamazepine ErCarbamazepine | 22 | $3,595 |
| Entacapone | 25 | $2,975 |
| Memantine Hcl | 113 | $2,930 |
| Levetiracetam | 127 | $2,920 |
| Donepezil Hcl | 208 | $2,666 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 90 | $1,998 |
| Divalproex Sodium | 32 | $1,923 |
| Gabapentin | 124 | $1,776 |
| Lacosamide | 17 | $1,333 |
| Propranolol Hcl ErPropranolol Hcl | 39 | $1,126 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieBotox, Ubrelvy | $629 | $89,25777 claims |
| PfizerNurtec Odt | $320 | $13,28913 claims |
| Upsher-smith Laboratories LLCTopiramate | $17 | $28829 claims |
| Amneal Pharmaceuticals LLCPyridostigmine Bromide | $300 | $26315 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 86 neurology providers in Rhode Island.
Other neurology in Providence
- Stephen SallowayProvidence$329K
- Syed RizviProvidence$160K
- John EastonProvidence$112K
- Saima ChaudhryProvidence$90K
- Monica DhakarProvidence$45K
- Jeffrey WishikProvidence$34K
- Prathana PrakashProvidence$31K
- Karen FurieProvidence$29K
- Chuang WuProvidence$14K
- Emily WeisbachProvidence$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.